Optimi Health Stock (OTC:OPTHF), Trade Ideas

Optimi Health Corp operates in developing a vertically integrated Canadian functional mushroom brand that focuses on the health and wellness sector. The company has one reportable operating segment being that of the farming, processing, and distribution of raw mushroom biomass. It also intends to cultivate, extract, process, and distribute strains of fungi products at its facilities located in Princeton, British Columbia.

Psyched New - option 1

Biotech

Cannabis

Psychedelics

AWKNF

BETRF

CMND

FLHLF

MASSIVE INTERACTIVE NV by Massive Interactive, Inc.

HUGE

MDXXF

MNMD

OPTHF

RED LIGHT HOLLAND CORP by Red Light Holland Corp.

TRUFF

Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans&#39; Trips And More

Psyched

AGNPF

ATAI

CMPS

DRUG

ENVB

GHRS

IXHL

LSDI

PSIL

SILO

Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna &amp; More

ivan-sanford-p0QvrrFckcA-unsplash

News

Contracts

Legal

Management

Global

Optimi To Supply Psilocybin For New Zealand&#39;s Mātai Medical Research Institute

OPTIMI HEALTH CORP by OPTIMI HEALTH CORP.

Optimi Health Corp

WisdomTree (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WT#NYSE">WT</a>) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.11 by 9.09 percent. This is a 71.43 percent increase over earnings of $0.07 per share from the same period last year. The company reported quarterly sales of $96.838 million which beat the analyst consensus estimate of $94.252 million by 2.74 percent. This is a 18.03 percent increase over sales of $82.044 million the same period last year.

Earnings

Earnings Beats

WisdomTree Q1 2024 Adj EPS $0.12 Beats $0.11 Estimate, Sales $96.838M Beat $94.252M Estimate

Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) reported quarterly earnings of $1.90 per share which missed the analyst consensus estimate of $2.17 by 12.44 percent. This is a 54.87 percent decrease over earnings of $4.21 per share from the same period last year. The company reported quarterly sales of $36.436 billion which beat the analyst consensus estimate of $33.075 billion by 10.16 percent. This is a 3.84 percent increase over sales of $35.089 billion the same period last year.

Earnings Misses

Phillips 66 Q1 2024 Adj EPS $1.90 Misses $2.17 Estimate, Sales $36.436B Beat $33.075B Estimate

Virtus Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTS#NASDAQ">VRTS</a>) reported quarterly earnings of $5.41 per share which met the analyst consensus estimate. This is a 28.81 percent increase over earnings of $4.20 per share from the same period last year. The company reported quarterly sales of $222.042 million which beat the analyst consensus estimate of $204.830 million by 8.40 percent. This is a 12.21 percent increase over sales of $197.874 million the same period last year.

VRTS

Virtus Inv Q1 2024 GAAP EPS $5.41, Inline, Sales $222.042M Beat $204.830M Estimate

The European Commission (EC), which has the authority to approve medicines for the European Union (EU), will now review the CHMP recommendation. The final EC decision is expected in June 2024.

Bristol Myers Says EMA's CHMP Recommended Approval Of Opdivo Combination With Cisplatin, Gemcitabine For First-line Treatment Of Adult Patients With Unresectable Or Metastatic Urothelial Carcinoma

Oil States International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OIS#NYSE">OIS</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $(0.01) by 2200 percent. This is a 600 percent increase over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $167.26 million which missed the analyst consensus estimate of $190.07 million by 12.00 percent. This is a 14.75 percent decrease over sales of $196.20 million the same period last year.

Oil States International Q1 EPS $0.21 Beats $(0.01) Estimate, Sales $167.26M Miss $190.07M Estimate

US Silica Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLCA#NYSE">SLCA</a>) reported quarterly earnings of $0.20 per share which met the analyst consensus estimate. The company reported quarterly sales of $325.900 million which missed the analyst consensus estimate of $336.591 million by 3.18 percent. This is a 26.31 percent decrease over sales of $442.240 million the same period last year.

SLCA

US Silica Holdings Q1 2024 Adj. EPS $0.20, Inline, Sales $325.900M Miss $336.591M Estimate

Strategic Priorities and Business Update
Phillips 66 is executing its strategic priorities to increase mid-cycle adjusted EBITDA to $14 billion by 2025 and return over 50% of operating cash flow to shareholders. Since July 2022, the company has distributed $9.9 billion through share repurchases and dividends and is on pace to achieve its $13 billion to $15 billion target by year-end 2024.
Phillips 66 plans to monetize assets that no longer fit its long-term strategy. The company is progressing the potential divestiture of its retail marketing business in Germany and Austria. Completion of dispositions is subject to market and other conditions, including customary approvals.

Phillips 66 Says It Is Executing Its Strategic Priorities To Increase Mid-Cycle Adjusted EBITDA To $14B By 2025 And Return Over 50% Of Operating Cash Flow To Shareholders

Increasing 2024&nbsp;guidance
Roper now expects full year 2024 adjusted DEPS of&nbsp;$18.05&nbsp;-&nbsp;$18.25, compared to previous&nbsp;guidance&nbsp;of&nbsp;$17.85&nbsp;-&nbsp;$18.15.
For the&nbsp;second quarter&nbsp;of 2024, the Company expects adjusted DEPS of&nbsp;$4.42&nbsp;-&nbsp;$4.46.

Guidance

Roper Technologies Expects Q2 Adj EPS of $4.42-$4.46 Vs $4.49 Est, FY24 Adj EPS of $18.05-$18.25 (Prior $17.85-$18.15) Vs $18.12 Est

Newell Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) reported quarterly losses of $(0.00) per share which beat the analyst consensus estimate of $(0.07) by 98.57 percent. This is a 98.33 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $1.653 billion which beat the analyst consensus estimate of $1.644 billion by 0.52 percent. This is a 8.42 percent decrease over sales of $1.805 billion the same period last year.

Newell Brands Q1 2024 Adj EPS $(0.00) Beats $(0.07) Estimate, Sales $1.653B Beat $1.644B Estimate

Sensient Technologies Reiterates FY24 Diluted Earnings Per Share Of $2.80-$2.90 Vs. $2.98 Estimate, Projects Revenue To Grow At Mid-Single-Digit Rate On Local Currency Basis

B of A Securities analyst John Babcock downgrades Hertz Global Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) from Neutral to Underperform and lowers the price target from $9 to $3.

Downgrades

Price Target

Analyst Ratings

B of A Securities Downgrades Hertz Global Holdings to Underperform, Lowers Price Target to $3

AutoNation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>) reported quarterly earnings of $4.49 per share. This is a 28.62 percent decrease over earnings of $6.29 per share from the same period last year. The company reported $6.49 billion in sales this quarter. This is a 5.88 percent decrease over sales of $6.89 billion the same period last year.

AutoNation Q2 EPS $4.49 Down From $6.29 YoY, Sales $6.49B Down From $6.89B YoY

Wells Fargo analyst Colin Langan upgrades Visteon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VC#NASDAQ">VC</a>) from Underweight to Equal-Weight and raises the price target from $106 to $108.

Upgrades

Wells Fargo Upgrades Visteon to Equal-Weight, Raises Price Target to $108

Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) reported quarterly earnings of $7.55 per share which missed the analyst consensus estimate of $7.84 by 3.7 percent. The company reported quarterly sales of $13.679 billion which missed the analyst consensus estimate of $13.743 billion by 0.47 percent. This is a 0.19 percent increase over sales of $13.653 billion the same period last year.

CHTR

Charter Communications Q1 2024 GAAP EPS $7.55 Misses $7.84 Estimate, Sales $13.679B Miss $13.743B Estimate

Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) reported quarterly earnings of $1.90 per share which missed the analyst consensus estimate of $2.17 by 12.44 percent. This is a 54.87 percent decrease over earnings of $4.21 per share from the same period last year.

Phillips 66 Q1 2024 Adj EPS $1.90 Misses $2.17 Estimate

Needham analyst Laura Martin maintains Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) with a Buy and raises the price target from $160 to $210.

GOOG

GOOGL

Needham Maintains Buy on Alphabet, Raises Price Target to $210

B of A Securities analyst John Murphy upgrades Sonic Automotive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAH#NYSE">SAH</a>) from Underperform to Buy and raises the price target from $55 to $68.

B of A Securities Upgrades Sonic Automotive to Buy, Raises Price Target to $68

Sensient Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SXT#NYSE">SXT</a>) reported quarterly earnings of $0.79 per share which beat the analyst consensus estimate of $0.70 by 12.86 percent. This is a 1.25 percent decrease over earnings of $0.80 per share from the same period last year. The company reported quarterly sales of $384.67 million which beat the analyst consensus estimate of $367.80 million by 4.59 percent. This is a 4.24 percent increase over sales of $369.01 million the same period last year.

Sensient Technologies Q1 Adj $0.79 Beats $0.70 Estimate, Sales $384.67M Beat $367.80M Estimate

WIIM

Colgate-Palmolive shares are trading higher after the company reported a Q1 earnings beat and raised its FY24 sales growth guidance.

Colgate Raises FY24 Sales Growth Guidance From 1-4% To 2-5%

Optimi announces second tranche of C$1M secured for debt financing

Psychedelic stocks gain after FDA priority review for MDMA therapy

Oregon House passes bill to end hard drug decriminalization

ACRHF

ATNF

CRLBF

CURLF

CYBN

GTBIF

IMBBY

JAPAY

MMNFF

MYCOF

NUMIF

RVVTF

SEEL

SPRC

Press Releases

Optimi Health To Host MDMA Educational Quality Assurance Webinar For Clinicians And Practitioners

Financing

Optimi Announces Non-Brokered Private Placement

Health Care

Optimi Health Congratulates Lykos Therapeutics on FDA Priority Review of New Drug Application And Releases MDMA Production Video

Optimi Announces Closing of First Tranche of Non-Brokered Private Placement

Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University

Optimi Health Confirms Presenting Sponsorship at the 4th Annual Psychedelic Therapeutics and Drug Development Conference

General

Optimi Health Receives Finished Product Test Results and Certificate Of Analysis for GMP Natural Psilocybin Extract

Optimi Health Signs Psilocybin Supply Agreement With New Zealand-Based Mātai Medical Research Institute

Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)

Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research

CSE:OPTI

Optimi Health